Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative.

Among the different biomarkers predicting response in chronic lymphocytic leukemia (CLL), the most influential parameters are the mutational status of the IGHV genes and the presence of TP53 gene disruptions. Nevertheless, these important assessments are not readily available in most centers dealing...

ver descrição completa

Detalhes bibliográficos
Autores: Bosch, F, Navarro, B, Crespo, M, Alcoceba, M, Sanchez, JB, Tazon, B, Serrano, A, Alvarez, MG, Serrano, LG, Alonso-Torres, P, Villanueva, M, Loriente, C, Abrisqueta, P, Peiro, M, Garcia-Marco, JA, Gonzalez, M, Terol, MJ
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Recursos:INCLIVA
Repositorio:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
OAI Identifier:oai:incliva.fundanetsuite.com:p15448
Acesso em linha:https://incliva.portalinvestigacion.com/publicaciones/15448
Access Level:acceso abierto
Palavra-chave:CLL
IGHV mutational status
Laboratory network
TP53 gene mutations
id ES_48d4dcd54ef1c4801a12b7c206f2e52b
oai_identifier_str oai:incliva.fundanetsuite.com:p15448
network_acronym_str ES
network_name_str España
repository_id_str
spelling Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative.Bosch, FNavarro, BCrespo, MAlcoceba, MSanchez, JBTazon, BSerrano, AAlvarez, MGSerrano, LGAlonso-Torres, PVillanueva, MLoriente, CAbrisqueta, PPeiro, MGarcia-Marco, JAGonzalez, MTerol, MJCLLIGHV mutational statusLaboratory networkTP53 gene mutationsAmong the different biomarkers predicting response in chronic lymphocytic leukemia (CLL), the most influential parameters are the mutational status of the IGHV genes and the presence of TP53 gene disruptions. Nevertheless, these important assessments are not readily available in most centers dealing with CLL patients. To provide this molecular testing across the country, the Spanish Cooperative Group on CLL (GELLC) established a network of four analytical reference centers. A total of 2153 samples from 256 centers were analyzed over a period of 30 months. In 9% of the patients, we found pathological mutations in the TP53 gene, whereas 48.96% were classified as IGHV unmutated. Results of the satisfaction survey of the program showed a Net Promoter Score of 85.15. Building a national network for molecular testing in CLL allowed the CLL population a broad access to complex biomarkers analysis that should translate into a more accurate and informed therapeutic decision-making.SPRINGER2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://incliva.portalinvestigacion.com/publicaciones/15448ANNALS OF HEMATOLOGYISSN: 09395555ISSNe: 14320584reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVAinstname:INCLIVAInglésinfo:eu-repo/semantics/openAccessoai:incliva.fundanetsuite.com:p154482026-06-07T16:35:31Z
dc.title.none.fl_str_mv Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative.
title Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative.
spellingShingle Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative.
Bosch, F
CLL
IGHV mutational status
Laboratory network
TP53 gene mutations
title_short Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative.
title_full Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative.
title_fullStr Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative.
title_full_unstemmed Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative.
title_sort Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative.
dc.creator.none.fl_str_mv Bosch, F
Navarro, B
Crespo, M
Alcoceba, M
Sanchez, JB
Tazon, B
Serrano, A
Alvarez, MG
Serrano, LG
Alonso-Torres, P
Villanueva, M
Loriente, C
Abrisqueta, P
Peiro, M
Garcia-Marco, JA
Gonzalez, M
Terol, MJ
author Bosch, F
author_facet Bosch, F
Navarro, B
Crespo, M
Alcoceba, M
Sanchez, JB
Tazon, B
Serrano, A
Alvarez, MG
Serrano, LG
Alonso-Torres, P
Villanueva, M
Loriente, C
Abrisqueta, P
Peiro, M
Garcia-Marco, JA
Gonzalez, M
Terol, MJ
author_role author
author2 Navarro, B
Crespo, M
Alcoceba, M
Sanchez, JB
Tazon, B
Serrano, A
Alvarez, MG
Serrano, LG
Alonso-Torres, P
Villanueva, M
Loriente, C
Abrisqueta, P
Peiro, M
Garcia-Marco, JA
Gonzalez, M
Terol, MJ
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv CLL
IGHV mutational status
Laboratory network
TP53 gene mutations
topic CLL
IGHV mutational status
Laboratory network
TP53 gene mutations
description Among the different biomarkers predicting response in chronic lymphocytic leukemia (CLL), the most influential parameters are the mutational status of the IGHV genes and the presence of TP53 gene disruptions. Nevertheless, these important assessments are not readily available in most centers dealing with CLL patients. To provide this molecular testing across the country, the Spanish Cooperative Group on CLL (GELLC) established a network of four analytical reference centers. A total of 2153 samples from 256 centers were analyzed over a period of 30 months. In 9% of the patients, we found pathological mutations in the TP53 gene, whereas 48.96% were classified as IGHV unmutated. Results of the satisfaction survey of the program showed a Net Promoter Score of 85.15. Building a national network for molecular testing in CLL allowed the CLL population a broad access to complex biomarkers analysis that should translate into a more accurate and informed therapeutic decision-making.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://incliva.portalinvestigacion.com/publicaciones/15448
url https://incliva.portalinvestigacion.com/publicaciones/15448
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv SPRINGER
publisher.none.fl_str_mv SPRINGER
dc.source.none.fl_str_mv ANNALS OF HEMATOLOGY
ISSN: 09395555
ISSNe: 14320584
reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname:INCLIVA
instname_str INCLIVA
reponame_str r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
collection r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407384855642112
score 15,198674

Registos relacionados